Skip to main content

Table 1 Breed, sex, hair type, housing conditions and the number of dogs included in the study and receiving concomitant medication at enrolment

From: Efficacy of a formulation of sarolaner/moxidectin/pyrantel (Simparica Trio®) for the prevention of Thelazia callipaeda canine eyeworm infection

Characteristics

G1 (n = 62)

G2 (n = 63)

n

%

n

%

Breed

 Purebred

51

82.3

51

81.0

 Non-purebred

11

17.7

12

19.0

Animal spends time

 Indoors and outdoors

19

30.6

20

31.7

 Mostly outdoors

43

69.4

43

68.3

Sex

 Male

31

50.0

41

65.1

 Female

31

50.0

22

34.9

Hair type

 Long

9

14.5

11

17.5

 Medium

20

32.3

14

22.2

 Short

33

53.2

38

60.3

Therapeutic/prophylactic medication

 On medication

2

3.2

4

6.3

 Not on medication

60

96.8

59

93.7

  1. G1: control group consisting of sarolaner (Simparica®). G2: investigated veterinary product consisting of sarolaner/moxidectin/pyrantel (Simparica Trio®)
  2. n: number of dogs, %: percentage of all dogs